neratinib after trastuzumab-based adjuvant therapy in her 2 positive breast cancer (extenet)
Published 5 years ago • 171 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
6:47
extended adjuvant therapy for her2-positive early breast cancer
-
2:48
the extenet study & management of her2 breast cancer
-
8:12
her2 breast cancer: neratinib’s role as adjuvant therapy
-
8:21
extended adjuvant therapy for her2-positive breast cancer
-
1:37
dr. traina on conversations on extended adjuvant therapy with neratinib in her2 breast cancer
-
7:23
extended adjuvant therapy in her2-positive disease
-
1:19
dr. pegram discusses the use of neratinib in her2 breast cancer
-
0:53
eleanor: real-world study of extended adjuvant neratinib in her2 /hr early breast cancer
-
1:02
dr. mohammad jahanzeb on neratinib and trastuzumab in her2-positive breast cancer
-
5:24
the extenet trial
-
1:14
dr. hamilton on how neratinib targets her2 breast cancer
-
3:58
post-adjuvant therapy for her2 breast cancer
-
5:24
the extenet trial
-
8:47
sramila aithal, md | neratinib and dose escalation | optimizing therapy for her2 disease
-
2:51
breast cancer: extended adjuvant therapy and cost factors
-
9:35
neratinib in her2 breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
5:21
study of neratinib for patients with her2-positive breast cancer with brain metastases
-
1:31
current treatment options for patients with her2-positive metastatic breast cancer